Developer docs
API playgroundTry for free, no card

Search company profiles

Entos Pharmaceuticals

Full company profile

uuid0000xua

Namestring
Entos Pharmaceuticals
Legal namestring
Entos Pharmaceuticals
Websiteurl
entospharma.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Entos Pharmaceuticals is a clinical-stage biotech company founded in Edmonton, Canada, that develops genetic medicines using its proprietary Fusogenix PLV (Proteo-Lipid Vehicle) drug delivery platform. The platform is built on FAST (Fusion Associated Small Transmembrane) proteins, which the company's scientific founder Roy Duncan discovered at Dalhousie University; these proteins catalyze direct membrane fusion between nanoparticles and target cell plasma membranes, enabling cytoplasmic delivery of RNA, DNA, and gene editing payloads while bypassing endosomal entrapment and avoiding the liver tropism and immunogenicity constraints of conventional lipid nanoparticle systems. The company complements the core biology with two proprietary technology layers: Fusogenix AIM (Advanced Interactive Modules) for precision cell- and tissue-specific targeting, and FOCUS-AI, an in-house AI workflow trained on years of iterative formulation data that designs bespoke PLV compositions for different indications.

Entos's clinical and preclinical pipeline spans three core programs: ENTLEP001, a leptin-encoding gene therapy for obesity and congenital generalized lipodystrophy that is advancing toward IND-enabling activities; ENTSTAR001, an ocular gene therapy delivering the full-length ABCA4 gene for Stargardt disease; and ENTVAX002, a plasmid DNA COVID-19 booster vaccine currently in a Phase I/II clinical trial (NCT06436911). The platform also underpins lung-targeted formulations and rare neuromuscular programs such as an L-CMD gene therapy collaboration with the L-CMD Research Foundation. Specialized formulations include Systemic, Ocular, Lung, and Vaccine PLV variants.

The company operates a partnership- and licensing-driven business model with no product revenue. It monetizes the platform through co-development agreements, out-licensing of pipeline assets, and non-dilutive grant funding, with Eli Lilly as a flagship research and collaboration partner and the Bill & Melinda Gates Foundation listed among its valued partners. CureDuchenne Ventures has invested to support a Duchenne muscular dystrophy program, and the California Institute for Regenerative Medicine provided a $4M grant for ENTLEP001 IND-enabling work. Entos has a wholly-owned US spinout, Aegis Life Inc., dedicated to vaccine commercialization, and operates GMP manufacturing in Carlsbad, California, alongside its Edmonton, San Diego, and London offices.

Short descriptiontext

Entos Pharmaceuticals is a clinical-stage biotech developing genetic medicines via its Fusogenix PLV non-viral delivery platform, leveraging FAST fusion proteins to deliver RNA, DNA, and gene editing payloads directly into cells across metabolic, ocular, vaccine, and rare disease indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdmonton, Canada
HQ citystring
Edmonton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-viral gene delivery, genetic medicines platform, fusion protein therapeutics, RNA DNA delivery, clinical-stage biotechnology
Industry5 codes
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Genetic Medicine Drug Delivery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Genetic Medicine Development & Licensing
TypeLicensing Royalties
Description

Entos develops proprietary genetic medicine pipeline assets using its Fusogenix PLV platform and seeks to partner or license programs with large pharmaceutical companies for co-development and commercialization. Revenue would be generated through upfront payments, milestone payments, and royalties on net sales.

entospharma.com
2Research Collaborations & Strategic Partnerships
TypeProfessional Services
Description

Co-development agreements with pharmaceutical partners and research foundations (e.g., Eli Lilly, L-CMD Research Foundation) providing research funding, development milestones, and potential commercialization rights.

entospharma.com
3Grant Funding
TypeManaged Services
Description

Non-dilutive funding from government and non-profit organizations such as the California Institute for Regenerative Medicine ($4M grant for ENTLEP001 IND-enabling activities).

streetinsider.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Fusogenix PLV
Description

A fusion-powered drug delivery platform for RNA and DNA genetic medicines, utilizing FAST (Fusion Associated Small Transmembrane) proteins for direct cell membrane fusion delivery.

entospharma.com
Core offering1 text field

Entos Pharmaceuticals develops and licenses the Fusogenix PLV drug delivery platform — a fusion-protein-based non-viral system for delivering RNA, DNA, and gene editing payloads directly into the cytoplasm of target cells. The company advances a clinical-stage pipeline of genetic medicines including a leptin gene therapy (ENTLEP001) for obesity and congenital generalized lipodystrophy, an ABCA4 gene therapy (ENTSTAR001) for Stargardt disease, and a COVID-19 booster DNA vaccine (ENTVAX002) currently in Phase I/II trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ENTVAX002 COVID-19 booster vaccine demonstrated longer durability, stronger T-cell response, and fridge-stable formulation in Phase I/II clinical trial.
+2 more records
Product overview1 text field

Entos Pharmaceuticals is a biotech company developing genetic medicines using its proprietary Fusogenix PLV (Proteoliposome Vesicle) platform. The platform utilizes FAST (Fusion Associated Small Transmembrane) proteins to enable direct fusion delivery of nucleic acids into cells, bypassing endocytosis. The core products include ENTLEP001 (gene therapy for obesity/metabolic disease), ENTSTAR001 (gene therapy for Stargardt disease), and ENTVAX002 (COVID-19 booster vaccine in phase I/II trials). The platform includes specialized formulations for systemic, ocular, lung, and vaccine applications, enhanced by AI-powered FOCUS-AI formulation design and Fusogenix AIM precision targeting technology.

Product and service1 record
1Fusogenix PLV Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

Entos Pharmaceuticals and the L-CMD Research Foundation are collaborating to develop a curative gene therapy for LMNA-related congenital muscular dystrophy (L-CMD), a fatal condition affecting at least 200 children worldwide with no existing treatments. The partnership leverages Entos's Fusogenix PLV non-viral delivery platform with novel gene editing approaches and muscle-targeted formulations to create redosable, potentially curative therapies. The organizations aim to utilize emerging FDA regulatory pathways to accelerate access for patients.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Eli Lilly and Entos Pharmaceuticals entered a research and collaboration agreement focused on the Fusogenix PLV platform technology. Lilly is listed as a valued partner on Entos's website and has invested through its corporate venture arm, representing a major strategic pharma partnership.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Aegis Life Inc. is a US-based spinout company launched by Entos to support its global vaccine commercialization strategy. Aegis Life received investment to continue development of DNA-encoded therapeutic antibodies against infectious diseases using the Fusogenix PLV platform. Aegis Life operates as a separate entity leveraging Entos technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Acuitas is a Canadian clinical-stage company developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, including mRNA vaccines and gene therapies. It is a direct competitor in non-viral nucleic acid delivery and supplies LNPs used in approved COVID-19 vaccines.

TypeEmerging player
Description

Bio-Path develops Pbi-shRNA and neutral lipid delivery technology (DNABLOC) for nucleic acid therapeutics. Comparable as a clinical-stage company using proprietary lipid-based delivery for systemic gene therapy and rare disease applications.

TypeDirect peer
Description

Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease using both LNP delivery and base editing technologies. Comparable as a clinical-stage platform company using non-viral delivery for systemic genetic medicines targeting metabolic disease.

TypeBroad incumbent
Description

Moderna is the largest mRNA therapeutics company, with approved vaccines and a deep pipeline including gene therapies (e.g., via its acquisition of OriCiro Genomics). It is a broad incumbent competing in nucleic acid delivery across vaccines, rare disease, and oncology.

TypeDirect peer
Description

Arcturus develops lipid-mediated delivery systems for mRNA and gene editing therapeutics, including LUNAR® technology targeting liver and non-liver tissues. Comparable as a clinical-stage platform company with proprietary non-viral delivery and pipeline assets across rare disease and infectious disease.

TypeDirect peer
Description

Generation Bio develops non-viral lipid nanoparticle-based gene therapies for rare diseases including hemophilia A. Comparable as a clinical-stage non-viral gene therapy company targeting rare genetic diseases with redosable delivery technology.

TypeEmerging player
Description

Intravacc develops vaccine delivery technologies and novel adjuvants including non-viral platforms. Comparable as an emerging platform player in vaccine delivery with overlapping interest in nucleic acid-based vaccine formulations.

TypeBroad incumbent
Description

BioNTech is a leading mRNA therapeutics and vaccine company with multiple approved products and a broad pipeline spanning oncology, infectious disease, and rare disease. It is a broad incumbent developing its own proprietary non-viral delivery innovations and competing in the same nucleic acid delivery space.

TypeEmerging player
Description

Precision BioSciences develops in vivo and ex vivo gene editing therapies using ARCUS, a proprietary homing endonuclease platform. Comparable as an emerging genetic medicines platform pursuing non-viral delivery and rare disease indications.

TypeEmerging player
Description

Cibus Bio is an early-stage mRNA-based genetic medicines company focused on non-viral delivery of mRNA immunotherapies and vaccines. Comparable as an emerging player in the non-viral nucleic acid delivery space with overlapping therapeutic indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Entos Pharmaceuticals

Genetic Medicine Drug Delivery Platformentospharma.com

Entos Pharmaceuticals is a clinical-stage biotech developing genetic medicines via its Fusogenix PLV non-viral delivery platform, leveraging FAST fusion proteins to deliver RNA, DNA, and gene editing payloads directly into cells across metabolic, ocular, vaccine, and rare disease indications.

What Entos Pharmaceuticals does

Entos Pharmaceuticals is a clinical-stage biotech company founded in Edmonton, Canada, that develops genetic medicines using its proprietary Fusogenix PLV (Proteo-Lipid Vehicle) drug delivery platform. The platform is built on FAST (Fusion Associated Small Transmembrane) proteins, which the company's scientific founder Roy Duncan discovered at Dalhousie University; these proteins catalyze direct membrane fusion between nanoparticles and target cell plasma membranes, enabling cytoplasmic delivery of RNA, DNA, and gene editing payloads while bypassing endosomal entrapment and avoiding the liver tropism and immunogenicity constraints of conventional lipid nanoparticle systems. The company complements the core biology with two proprietary technology layers: Fusogenix AIM (Advanced Interactive Modules) for precision cell- and tissue-specific targeting, and FOCUS-AI, an in-house AI workflow trained on years of iterative formulation data that designs bespoke PLV compositions for different indications.

Entos's clinical and preclinical pipeline spans three core programs: ENTLEP001, a leptin-encoding gene therapy for obesity and congenital generalized lipodystrophy that is advancing toward IND-enabling activities; ENTSTAR001, an ocular gene therapy delivering the full-length ABCA4 gene for Stargardt disease; and ENTVAX002, a plasmid DNA COVID-19 booster vaccine currently in a Phase I/II clinical trial (NCT06436911). The platform also underpins lung-targeted formulations and rare neuromuscular programs such as an L-CMD gene therapy collaboration with the L-CMD Research Foundation. Specialized formulations include Systemic, Ocular, Lung, and Vaccine PLV variants.

The company operates a partnership- and licensing-driven business model with no product revenue. It monetizes the platform through co-development agreements, out-licensing of pipeline assets, and non-dilutive grant funding, with Eli Lilly as a flagship research and collaboration partner and the Bill & Melinda Gates Foundation listed among its valued partners. CureDuchenne Ventures has invested to support a Duchenne muscular dystrophy program, and the California Institute for Regenerative Medicine provided a $4M grant for ENTLEP001 IND-enabling work. Entos has a wholly-owned US spinout, Aegis Life Inc., dedicated to vaccine commercialization, and operates GMP manufacturing in Carlsbad, California, alongside its Edmonton, San Diego, and London offices.

Entos Pharmaceuticals firmographics

Firmographics
Name
Entos Pharmaceuticals
Legal name
Entos Pharmaceuticals
Website
https://entospharma.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Entos Pharmaceuticals is a clinical-stage biotech developing genetic medicines via its Fusogenix PLV non-viral delivery platform, leveraging FAST fusion proteins to deliver RNA, DNA, and gene editing payloads directly into cells across metabolic, ocular, vaccine, and rare disease indications.
Ownership category
akta.pro rank

Entos Pharmaceuticals industry classification

Industry
Product category
Genetic Medicine Drug Delivery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Non-viral gene delivery
  • Genetic medicines platform
  • Fusion protein therapeutics
  • RNA DNA delivery
  • Clinical-stage biotechnology

Where Entos Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Edmonton
HQ country
Canada
HQ region
North America

Offices5 records

Markets served

Entos Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Genetic Medicine Development & Licensing: Entos develops proprietary genetic medicine pipeline assets using its Fusogenix PLV platform and seeks to partner or license programs with large pharmaceutical companies for co-development and commercialization. Revenue would be generated through upfront payments, milestone payments, and royalties on net sales.
  2. Research Collaborations & Strategic Partnerships: Co-development agreements with pharmaceutical partners and research foundations (e.g., Eli Lilly, L-CMD Research Foundation) providing research funding, development milestones, and potential commercialization rights.
  3. Grant Funding: Non-dilutive funding from government and non-profit organizations such as the California Institute for Regenerative Medicine ($4M grant for ENTLEP001 IND-enabling activities).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Entos Pharmaceuticals product offering

Product offering

Core offering

Entos Pharmaceuticals develops and licenses the Fusogenix PLV drug delivery platform — a fusion-protein-based non-viral system for delivering RNA, DNA, and gene editing payloads directly into the cytoplasm of target cells. The company advances a clinical-stage pipeline of genetic medicines including a leptin gene therapy (ENTLEP001) for obesity and congenital generalized lipodystrophy, an ABCA4 gene therapy (ENTSTAR001) for Stargardt disease, and a COVID-19 booster DNA vaccine (ENTVAX002) currently in Phase I/II trials.

Product overview

Entos Pharmaceuticals is a biotech company developing genetic medicines using its proprietary Fusogenix PLV (Proteoliposome Vesicle) platform. The platform utilizes FAST (Fusion Associated Small Transmembrane) proteins to enable direct fusion delivery of nucleic acids into cells, bypassing endocytosis. The core products include ENTLEP001 (gene therapy for obesity/metabolic disease), ENTSTAR001 (gene therapy for Stargardt disease), and ENTVAX002 (COVID-19 booster vaccine in phase I/II trials). The platform includes specialized formulations for systemic, ocular, lung, and vaccine applications, enhanced by AI-powered FOCUS-AI formulation design and Fusogenix AIM precision targeting technology.

Differentiator

Problem solved

Functional benefit

Brands

  • Fusogenix PLV: A fusion-powered drug delivery platform for RNA and DNA genetic medicines, utilizing FAST (Fusion Associated Small Transmembrane) proteins for direct cell membrane fusion delivery.

Products and services

  • Fusogenix PLV Platform

Quantifiable outcome

  • ENTVAX002 COVID-19 booster vaccine demonstrated longer durability, stronger T-cell response, and fridge-stable formulation in Phase I/II clinical trial.
  • +2 more outcomes

Companies that use Entos Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles3 records

Entos Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Entos Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • L-CMD Research FoundationcoreStrategic or Co-development Partner · 20 April 2026Entos Pharmaceuticals and the L-CMD Research Foundation are collaborating to develop a curative gene therapy for LMNA-related congenital muscular dystrophy (L-CMD), a fatal condition affecting at least 200 children worldwide with no existing treatments. The partnership leverages Entos's Fusogenix PLV non-viral delivery platform with novel gene editing approaches and muscle-targeted formulations to create redosable, potentially curative therapies. The organizations aim to utilize emerging FDA regulatory pathways to accelerate access for patients.
  • Eli Lilly and CompanyflagshipStrategic or Co-development PartnerEli Lilly and Entos Pharmaceuticals entered a research and collaboration agreement focused on the Fusogenix PLV platform technology. Lilly is listed as a valued partner on Entos's website and has invested through its corporate venture arm, representing a major strategic pharma partnership.
  • Aegis Life Inc.coreOEM/ Whitelabel/ Licensing PartnerAegis Life Inc. is a US-based spinout company launched by Entos to support its global vaccine commercialization strategy. Aegis Life received investment to continue development of DNA-encoded therapeutic antibodies against infectious diseases using the Fusogenix PLV platform. Aegis Life operates as a separate entity leveraging Entos technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Entos Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Acuitas Therapeutics: Acuitas is a Canadian clinical-stage company developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, including mRNA vaccines and gene therapies. It is a direct competitor in non-viral nucleic acid delivery and supplies LNPs used in approved COVID-19 vaccines.
  • Verve Therapeutics: Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease using both LNP delivery and base editing technologies. Comparable as a clinical-stage platform company using non-viral delivery for systemic genetic medicines targeting metabolic disease.
  • Arcturus Therapeutics: Arcturus develops lipid-mediated delivery systems for mRNA and gene editing therapeutics, including LUNAR® technology targeting liver and non-liver tissues. Comparable as a clinical-stage platform company with proprietary non-viral delivery and pipeline assets across rare disease and infectious disease.
  • Generation Bio: Generation Bio develops non-viral lipid nanoparticle-based gene therapies for rare diseases including hemophilia A. Comparable as a clinical-stage non-viral gene therapy company targeting rare genetic diseases with redosable delivery technology.

Emerging players

  • Bio-Path Holdings: Bio-Path develops Pbi-shRNA and neutral lipid delivery technology (DNABLOC) for nucleic acid therapeutics. Comparable as a clinical-stage company using proprietary lipid-based delivery for systemic gene therapy and rare disease applications.
  • Intravacc: Intravacc develops vaccine delivery technologies and novel adjuvants including non-viral platforms. Comparable as an emerging platform player in vaccine delivery with overlapping interest in nucleic acid-based vaccine formulations.
  • Precision BioSciences: Precision BioSciences develops in vivo and ex vivo gene editing therapies using ARCUS, a proprietary homing endonuclease platform. Comparable as an emerging genetic medicines platform pursuing non-viral delivery and rare disease indications.
  • Cibus Bio (previously eTheRNA): Cibus Bio is an early-stage mRNA-based genetic medicines company focused on non-viral delivery of mRNA immunotherapies and vaccines. Comparable as an emerging player in the non-viral nucleic acid delivery space with overlapping therapeutic indications.

Broad incumbents

  • Moderna: Moderna is the largest mRNA therapeutics company, with approved vaccines and a deep pipeline including gene therapies (e.g., via its acquisition of OriCiro Genomics). It is a broad incumbent competing in nucleic acid delivery across vaccines, rare disease, and oncology.
  • BioNTech: BioNTech is a leading mRNA therapeutics and vaccine company with multiple approved products and a broad pipeline spanning oncology, infectious disease, and rare disease. It is a broad incumbent developing its own proprietary non-viral delivery innovations and competing in the same nucleic acid delivery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Entos Pharmaceuticals social profiles

Digital presence

Entos Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Entos Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles14 records

Entos Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Entos Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Entos Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entos Pharmaceuticals

What does Entos Pharmaceuticals do?

Entos Pharmaceuticals develops and licenses the Fusogenix PLV drug delivery platform — a fusion-protein-based non-viral system for delivering RNA, DNA, and gene editing payloads directly into the cytoplasm of target cells. The company advances a clinical-stage pipeline of genetic medicines including a leptin gene therapy (ENTLEP001) for obesity and congenital generalized lipodystrophy, an ABCA4 gene therapy (ENTSTAR001) for Stargardt disease, and a COVID-19 booster DNA vaccine (ENTVAX002) currently in Phase I/II trials.

Is Entos Pharmaceuticals a public or private company?

Entos Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Entos Pharmaceuticals founded?

Entos Pharmaceuticals was founded in 2017. It employs 11 to 50 people.

Where is Entos Pharmaceuticals based?

Entos Pharmaceuticals is headquartered in Edmonton, Canada, in the North America region.

How does Entos Pharmaceuticals make money?

Three revenue lines are on record. Genetic Medicine Development & Licensing is the primary driver. The others are research Collaborations & Strategic Partnerships and grant Funding.

Who are Entos Pharmaceuticals's main competitors?

Direct peers on record are Acuitas Therapeutics, Verve Therapeutics, Arcturus Therapeutics and Generation Bio. Emerging players are Bio-Path Holdings, Intravacc, Precision BioSciences and Cibus Bio (previously eTheRNA). Broad incumbents are Moderna and BioNTech.

Does Entos Pharmaceuticals have an API?

No public API is recorded for Entos Pharmaceuticals.

What industry is Entos Pharmaceuticals in?

Entos Pharmaceuticals's product category is Genetic Medicine Drug Delivery Platform. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital JournalCanada’s biotech moment: Where scientific depth is meeting commercial scaleCanada is experiencing a biotech sector maturation where foundational scientific contributions are increasingly being translated into commercial-scale domestic biopharma businesses, supported by federal Biomanufacturing and Life Sciences Strategy investments since the pandemic. Specific companies including AbCellera (Vancouver), Entos Pharmaceuticals (Edmonton), STEMCELL Technologies (British Columbia), and OmniaBio (Hamilton) are cited as examples of firms advancing from discovery platforms to clinical assets and biomanufacturing capabilities. The sector faces structural challenges including limited scale-up capital compared to US hubs, thin commercial leadership talent, and the perennial risk of promising companies being acquired before building enduring domestic industrial champions.BioWorldEntos and L-CMD Research Foundation collaborateEntos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation to develop a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD). The partnership aims to address this rare neuromuscular disease through gene therapy.Financial PostEntos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular DystrophyEntos Pharmaceuticals has announced a collaboration with the L-CMD Research Foundation to develop a potentially curative genetic therapy for LMNA-related congenital muscular dystrophy, a fatal condition affecting at least 200 children worldwide with no existing treatments or cures. The partnership will combine Entos's Fusogenix PLV drug delivery platform with novel gene editing approaches to create redosable therapies targeting this currently untreatable disease. The companies aim to leverage emerging FDA regulatory pathways to accelerate development of treatments for this rare pediatric condition.Business Wire BlogEntos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular DystrophyEntos Pharmaceuticals and the L-CMD Research Foundation announced a collaboration to develop a curative gene therapy for LMNA-related congenital muscular dystrophy (L-CMD), a severe form of fatal muscular dystrophy affecting at least 200 children worldwide with no existing treatments or cures. The partnership leverages Entos' Fusogenix PLV non-viral delivery platform with novel gene editing approaches and muscle-targeted formulations to create potentially curative therapies. The organizations aim to utilize emerging FDA regulatory pathways to make these genetic medicines accessible to patients suffering from this currently untreatable condition.CureduchenneCureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene TherapyCureDuchenne Ventures announced a $1M initial investment in Entos Pharmaceuticals to develop a redosable, full-length dystrophin gene therapy for Duchenne muscular dystrophy. The therapy will use Entos' Fusogenix PLV non-viral delivery platform, which allows multiple doses. Entos plans to share details at the CureDuchenne 2025 conference in San Antonio.NewswireCureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene TherapyCureDuchenne Ventures announced a $1M investment in Entos Pharmaceuticals to develop a redosable, full-length dystrophin gene therapy for Duchenne muscular dystrophy. The therapy uses Entos' Fusogenix PLV delivery platform, which allows multiple doses and avoids pre-existing immunity issues. Entos will present plans at the CureDuchenne 2025 conference in San Antonio.PR NewswireCureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene TherapyCureDuchenne Ventures announced a $1M investment in Entos Pharmaceuticals to develop a redosable, full-length dystrophin gene therapy for Duchenne muscular dystrophy. The therapy uses Entos' Fusogenix PLV delivery platform, which allows multiple doses and avoids pre-existing immunity issues. Entos will present plans at the CureDuchenne 2025 conference in San Antonio.EntospharmaEntos to Develop Dystrophin Therapy for DMD with CureDuchenneCureDuchenne Ventures announced an initial $1 million investment in Entos Pharmaceuticals on May 22, 2025, to develop a muscle-targeting gene therapy for Duchenne muscular dystrophy using Entos's Fusogenix PLV delivery platform. The platform enables redosable, non-viral delivery of full-length dystrophin, potentially overcoming limitations of current AAV-based gene therapies including pre-existing immunity restrictions. Entos will present details of the program at the CureDuchenne 2025 FUTURES National Conference in San Antonio, Texas.Pulse 2.0Entos Pharmaceuticals: $198.5 Million Partnership With The Governments Of Canada And Alberta SignedEntos Pharmaceuticals announced a $62 million investment from the Government of Canada, plus $15.5 million from Alberta, totaling $77.5 million. The funds will support a $198.5 million project to build an R&D center and GMP biomanufacturing facility in Edmonton, Alberta. The facility aims to foster collaborations and strengthen Canada's life sciences sector.Business Wire BlogEntos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation TherapeuticsEntos Pharmaceuticals announced a $77.5 million investment from the governments of Canada and Alberta to support a $198.5 million project for a new R&D centre and GMP biomanufacturing facility in Edmonton. This development aims to accelerate the production of Fusogenix PLV therapeutics and strengthen Canada's domestic life sciences ecosystem through collaborations with academic institutions and industry partners like Eli Lilly.